My thoughts on their quarterly:

They provided guidance at the beginning of the year of expected $24-26M revenue, and signs show they appear on track to hit this. 

Additional good news during the quarter was the value of the Defence pilot order increasing from ~$1M to ~$2 million. That’s not a small pilot and having Defence as a client is always a strong social proof. 

What remains unclear to me with Vection is when realistically we could expect operational leverage from them. We see from the cashflow report that dollars spent on product manufacturing & operating costs nearly equaled incoming cash ($5,504,000 vs$ 5,674,000).

They would be developing a lot of customisation in these training workflows which can likely keep operating costs high for a while. This is in part what led to the $3M cash burned in the quarter. The market would be questioning if the $11M cash left will be sufficient to reach large enough milestones before a cap raise is necessary. 

What they do remains very interesting, and with use cases exploding, I wouldn’t be surprised to see them deliver more good news in the next few years, so I’ll keep close tabs on them. 

Source: Commented on them alongside 4 other reports in my Substack this week.

This should be interesting - using artificial intelligence and extended reality to train technicians. Is this the new online apprenticeship and/or CISCO/Microsoft certifications?

March 2 (Reuters) - Vection Technologies Ltd (VR1) :

• AWARD OF A MAJOR DEFENCE PILOT ORDER OF ABOUT A$1 MILLION
• FURTHER SECURES ITS A$24-26 MILLION REVENUE GUIDANCE FOR FISCAL 2023
• INITIAL PILOT FORMS PART OF A LARGER TENDER OF UP TO ABOUT A$30 MILLION

I am sure there's some interesting info in this report, and it'll be helpful to understand the company. I'd just caution that it is not independent and should be read as such.

In depth research performed by EDISON into VR1 with some comparisons to large and small competitors

29/11/2022

Vection Technologies has engaged Edison to produce in-depth and regular research on the company, which is available to everyone. It is hoped this research will raise the visibility of Vection Technologies and enable investors of all classes, in any country, to develop an improved understanding of the business.

Vection Technologies - Enterprise-grade metaverse | Edison (edisongroup.com)

DISC small parcel held in RL and SM (both in the red atm)

A big jump in Revenue! Looks like the company is on the right track (and in a hot sector).

Preliminary final report released:

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02562578-6A1107407?access_token=83ff96335c2d45a094df02a206a39ff4

Nice announcement today from Vection Technologies - 30% Increase in Total Contract Value.

Increased Revenue growth

Partnerships Include Volkswagen, Armani

Enterprise-Sales--TCV-Update.PDF

Disc - Hold in RL and SM.

Vection Technologies Ltd (ASX:VR1) announced today it has received firm commitments, from predominantly

technology focused domestic and international institutional investors, for an equity funding round of $12 million (Placement).

Highlights:

? Placement to build capacity for growth, with Australian and global institutional investors joining the Company’s share register

? Acceleration of aggressive global acquisition strategy targeting the XR & metaverse enterprise technology sector,

anticipating the fierce competition of global technology corporations looking for XR & metaverse exposure

? Aligns with Vection’s history of acquisitions

? Strengthened balance sheet post Placement with ~$20 million cash on hand

“Vection Technologies’ Board of Directors have received this overwhelming institutional investor interest with support, combining a stronger balance sheet with a clear alignment of M&A and corporate strategy to yield compelling returns for all stakeholders.

We are pleased to welcome these high-calibre investors to our Company” said Gianmarco Biagi, Managing Director of Vection Technologies.

“As we anticipate increased M&A interest in the XR & metaverse space, we believe that building size is a critical stepping stone for the global success of Vection Technologies and its stakeholders. This strategic funding round will enable the Company to aggressively target M&A transactions globally, aligned with our strong history of well-executed acquisitions with a keen focus on our shareholders interest.”

The Placement of $12 million (before costs of the offer) will be completed through the issue of 60 million fully paid ordinary shares (Shares) at an issue price of 20c per Share. The Placement is expected to settle on Thursday 2 December 2021.

The Placement Shares are proposed to rank equally with the existing shares of the Company.

What a ride for Vection!

Up 50% last week. Now they have put a trading halt until 1 Dec or sooner...... anybody with guesses??

With the recent success of Crypto ETF, I think we are ripe for an Virtual Reality ETF.

Vection would certainly be one of the inclusions. And what would happen to the share price should it be included in a couple of VR etfs?

Disclosure: I hold.

VECTION CONTINUES SECOND HALF MOMENTUM

VECTION ACHIEVES ~300% GROWTH IN SECOND HALF CLIENT ORDERS

Highlights: 

• ~300% increase in second half clients orders to date to ~$2.1M (First half revenue $740k)
•  Second half clients include Volkswagen, Trenitalia, Olivetti TIM Group, Unopiù, CompuGroup Medical (CGM), DELL Platinum and OEM Partner, JMC Group, the Chinese University of Hong Kong and Armani, among others
• Launch of Vection Healthcare & Pharma vertical and strong advancement on overarching building blocks
•  Pandemic-led extended E.U. client payment terms resulting in ~$1M in debtors at quarter end, not represented in the quarterly cash receipts
•  Strong cash balance of ~$6.1M enables the Company to pursue it growth objectives and aggressive M&A strategy from a position of strength
•  Strong focus on the Digital Transformation (DX) trend, also supported by the ~$1.2 trillion NextGen European Recovery plan, including $51 billion for DX in Italy and ~$230 billion across Europe
•  Investor call to be held on Tuesday 4 May 2021 at 12pm AEST

.....Investor Presentation and Call:

Vection’s management will host a conference call on Tuesday 4 May 2021 at 12pm AEST to discuss the investor presentation (slides to be released separately to the market on Monday 3 May 2021) and to provide an update of the Company’s business strategy and financial performance. Participants must register in advance for the investor call using the following link to receive dial-in details: https://zoom.us/webinar/register/WN_g5cGX5HTTnmxSpWdVVQxWg After registering, you will receive a confirmation email containing information about joining the webinar.

DISC: Small holding

11/3/21   LAUNCH OF HEALTHCARE & PHARMA SOLUTIONS VERTICAL

FIRST MILESTONE IN THE 2021 VERTICALIZATION STRATEGY

Highlights:

•  Vection strongly accelerates its international growth strategy with the launch of its Healthcare & Pharma Solutions Division
•  Vection joins forces with highly experienced team with former roles in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Novartis, Boehringer Ingelheim and Dompé Farmaceutici
•  Strong commitment by the executive team with joint division ownership and strong opportunities pipeline anticipated to come to fruition from April 2021
•  Strong ability to attract senior industry-specific executives key for the Company’s growth acceleration
•  Expansion of Vection’s footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments leveraging its existing core technology stack
•  Strategic division for continued growth during the current pandemic aligned with the digital transformation trend in healthcare
•  First milestone in the 2021 Verticalization strategy achieved
•  A brief presentation of the Healthcare & Pharma Solutions division is appended to this announcement

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02352337-6A1024054?access_token=83ff96335c2d45a094df02a206a39ff4       ...also includes small presentation

19/3/21     ADDITIONAL INFORMATION ON THE HEALTHCARE & PHARMA DIVISION

Further the announcement dated 11 March 2021, the Company provides the following additional information:

•  Following extensive negotiations, the Company has secured the strong commitment of Dr Centemeri through the incorporation of a joint venture company controlled by Vection at 60%, with 40% owned by Dr Centemeri (Division), a leading healthcare and pharma executive with senior experience in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb and AstraZeneca.
•  The key terms of the agreement with Dr Centemeri consist of his involvement in the new Division and his commitment as its Managing Director, to the achievement of expansion of Vection’s footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments as disclosed, which forms the basis of a comprehensive results driven business plan which is an integral part of his commitment.
•  Vection will provide funding for establishment costs of the Division pursuant to a comprehensive business plan underpinned by the commitment of Dr Centemeri. The initial agreement provides for the commitment of Dr Centemeri, the composition of the new Division, exclusivity, non-competition, business plan and cash flows and activities of the new company.
•  Vection controls the new Division on the basis of holding a 60% shareholding and retaining control of its board. The board composition is Dr Centemeri and 2 appointees of Vection.

see attached

Disc: Small holding

VECTION TECHNOLOGIES COLLABORATES WITH HP INC.

Real-time software company Vection Technologies (ASX:VR1) (Vection Technologies, Vection or the Company) is pleased to announce the execution of an Original Equipment Manufacturer (OEM) agreement with multinational technology company HP Inc (HP) 

The OEM collaboration will play a critical role inthe delivery of Virtual Reality (VR) integrted solutions (HP's VR hardware & Vections VR software) in over 170 countries via HP's g;obal network. This agreemen follows on from the entry of Vection's Mindesk in the HP Independant Software Vendor Partner Program:Virtual Reality tracking during August 2019.

Disc: I have a small holding

Real-time software company Vection Technologies Ltd (ASX:VR1) (Vection Technologies, Vection or the Company) is pleased to announce the launch of an innovative Augmented and Mixed reality (XR) interface for Computer Aided Design (CAD) software released with the latest Mindesk Suite 2021, during the most influential tech event in the world, the CES® 2021. CES® 2021,

The World’s Biggest Annual Consumer Electronics Show Vection Technologies will be officially launching its breakthrough Mindesk release at the world’s biggest annual consumer electronics show, the CES® 2021, an all-digital experience where the biggest names in the industry will be sharing their latest and greatest innovations online via the organisers media hub. CES® 2021 will officially take place from Monday 11th to Thursday 14th January 2021

An example video of Mindesk Suite 2021 integration with Varjo XR1 is available at the following link: https://youtu.be/6zs2wEfeeJQ

DISC: Another small holding